Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
May 03 2021 - 8:00AM
Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in
redosable gene therapies for rare diseases, announced today the
appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has
more than 25 years of global biotechnology experience, most
recently in the role of Senior Vice President, Head of US Business
at Alnylam Pharmaceuticals.
“We are excited to welcome Andy to the Krystal team at such an
exciting time for our lead investigational program B-VEC for DEB,
and the rest of our growing rare disease pipeline,” said Krish S.
Krishnan, chairman and chief executive officer of Krystal Biotech.
“He is an accomplished biotechnology executive who has successfully
launched several genetic medicines in the rare disease space and
will be a key asset for Krystal as we work towards our goal of
building a fully integrated biotechnology company with a strong
commercial capability.”
“I am thrilled to be joining Krystal and see tremendous
potential in the innovative technology platform and rapidly
maturing pipeline,” Andy commented. “I look forward to enhancing
the commercial capabilities at Krystal to achieve our ultimate goal
of bringing important medicines to patients in need.”
In his role of Senior Vice President, Head of U.S. Region at
Alnylam, Andy led the organization through multiple launches of
rare disease genetic medicines and was responsible for leading the
U.S. Business Account Teams, Market Access, Marketing, Patient
Services and Operations. Previously, Andy served as Alnylam’s
Vice President of Commercial Practice where he helped build out
Alnylam’s global commercial capabilities. Prior to Alnylam, Andy
held various roles across Commercial and Finance with Biogen,
Genzyme and Amgen. Andy received his MBA from Cornell University
and his undergraduate degree from the University of Wisconsin.
About Krystal BiotechKrystal Biotech,
Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company
leveraging its novel, redosable gene therapy platform and in-house
manufacturing capabilities to develop therapies to treat serious
rare diseases. For more information, please
visit http://www.krystalbio.com.
Forward-Looking StatementsAny statements in
this press release about future expectations, plans and prospects
for Krystal Biotech, Inc., including but not limited to statements
about the development of Krystal’s product candidates, such as
plans for the design, conduct and timelines of ongoing pre-clinical
and clinical trials of beremagene geperpavec (“B-VEC”), KB105,
KB104, KB301, KB407, and KB408; the clinical utility of B-VEC,
KB105, KB104, KB301, KB407 and KB408, and Krystal’s plans for
filing of regulatory approvals and efforts to bring B-VEC, KB105,
KB104, KB301, KB407 and KB408 to market; the market opportunity for
and the potential market acceptance of B-VEC, KB105, KB104, KB301,
KB407 and KB408; plans to pursue research and development of other
product candidates; the sufficiency of Krystal’s existing cash
resources; the unanticipated impact of COVID-19 on Krystal’s
business operations, pre-clinical activities and clinical trials;
and other statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, availability and timing of data from clinical trials,
whether results of early clinical trials or trials will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of product candidates including B-VEC, KB105,
KB104, KB301, KB407 and KB408, the sufficiency of cash resources
and need for additional financing and such other important factors
as are set forth under the caption “Risk Factors” in Krystal’s
annual and quarterly reports on file with the U.S. Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent Krystal’s views as of the
date of this release. Krystal anticipates that subsequent events
and developments will cause its views to change. However, while
Krystal may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be relied
upon as representing Krystal’s views as of any date subsequent to
the date of this release.
CONTACTS:
Investors:Whitney Ijemwijem@krystalbio.com
Media:Mary CoyleTellMed
Strategiesmary.coyle@tmstrat.com
Source: Krystal Biotech, Inc.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Oct 2023 to Oct 2024